Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial.
about
The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomicsClopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistanceThe rise of multiple imputation: a review of the reporting and implementation of the method in medical researchExploring predisposition and treatment response--the promise of genomicsComparison of delivery strategies for pharmacogenetic testing servicesPharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation?Future translational applications from the contemporary genomics era: a scientific statement from the American Heart AssociationUse of genetic data to guide therapy in arterial disease.Real-world efficiency of pharmacogenetic screening for carbamazepine-induced severe cutaneous adverse reactions.Diagnostic point-of-care tests in resource-limited settingsHuman genetics of tuberculosis: a long and winding road.Pharmacogenomics: Current State-of-the-ArtInterplay between genetic and clinical variables affecting platelet reactivity and cardiac adverse events in patients undergoing percutaneous coronary intervention.Implementation and utilization of genetic testing in personalized medicine.Pharmacogenomics and individualized medicine: translating science into practice.Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects.Pharmacogenetics in clinical practice: how far have we come and where are we going?Molecular oncology testing in resource-limited settings.Pharmacogenetics in Jewish populations.Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism.Understanding the economic value of molecular diagnostic tests: case studies and lessons learned.Tailored antiplatelet therapy and clinical adverse outcomes.A comparative pharmacodynamic study of ticagrelor versus clopidogrel and ticagrelor in patients undergoing primary percutaneous coronary intervention: the CAPITAL RELOAD studyAntidepressant prescribing in the precision medicine era: a prescriber's primer on pharmacogenetic tools.Genotype-based clinical trials in cardiovascular disease.Cardiovascular pharmacogenomics: the future of cardiovascular therapeutics?Clinical pharmacogenomics: opportunities and challenges at point of careScientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice.Pharmacogenomics in the pocket of every patient? A prototype based on quick response codes.Doubly blind: a systematic review of gender in randomised controlled trials.Genomics in cardiovascular disease.Are randomized trials obsolete or more important than ever in the genomic era?Pharmacogenetic testing: Current Evidence of Clinical Utility.The CYP2C19*17 variant is not independently associated with clopidogrel response.Pharmacogenomics in clinical practice and drug development.Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention.Using systems approaches to address challenges for clinical implementation of pharmacogenomics.The Coriell personalized medicine collaborative pharmacogenomics appraisal, evidence scoring and interpretation system.
P2860
Q26801867-47308C78-C757-4822-9C91-01044201BED7Q26822796-C2E21070-C45A-41F3-BB9D-C5AD79326C48Q26823542-D3BBF29F-A5A2-4B3B-9F21-BEB71C9415ADQ26824850-21225D74-0728-4570-9414-8B8201D7BF66Q26828889-15082932-287F-4CBD-8B2B-1AEE30ECE55DQ26851609-0F84801C-AFCF-445E-A8CD-25169C9DB477Q26860925-61B7B4DF-78C7-4D04-B74C-8EACFE5DB818Q27022443-78C90F60-C103-4848-A2F2-AE4EF67DD234Q30359686-10254B56-7EF0-4B6D-88C6-A57DF9B27168Q30978916-37F4899D-C56F-4090-B641-65987635FD87Q33578364-94CD99A3-1A33-46D2-83AE-50B141D6E380Q33590492-93A72AAF-426D-48E9-B81A-43779BC6EA20Q33624576-32E2AE6C-9905-4C04-89E7-C16115CBDEE6Q33891714-E4302485-D45D-4F15-B409-3AA321692CF0Q33933475-0B7595D8-8A93-4362-A95B-8EA408525468Q34147916-AB717776-8A2E-4374-AE7C-7A5A949211D2Q34297575-FB442DC9-506A-4284-84EE-C1ED7CEA1BC3Q34307589-44EDB4A9-A8B3-42F4-A7B4-F23150825F70Q34343365-76F1B55A-F696-4E47-A25B-147182982276Q34409732-2725AF43-5B5D-43DD-891C-31EFE11E4AC3Q34458720-7FD171CC-2786-477B-BE28-3151E5AEEAD6Q34536091-BF2FD9E3-FA09-4EA2-AE14-AE7E6DAABC38Q34608705-3B656368-CCD3-401E-8531-0491CC04ECEDQ35032042-B4E687BD-37DE-46CD-A309-BADB32AFAB53Q35126038-5A28B6B5-4845-4E6F-8D94-FA380F1C7715Q36274662-C4C1C19D-F18C-4B1F-B5B0-A615A4427DE9Q36393911-C8CBF026-D126-4596-B59A-4C8D7A0101F3Q36487290-1EE19602-1E9C-43C5-A20C-CA19BD091396Q36622897-2DEEEB05-BB0C-4C74-B8EE-2631C6841CA2Q36702588-D46A2BB1-1637-44BD-A0F9-76A42C7908F5Q36771188-232B4FC6-BD64-40A0-ABF7-878D2BC9B8F4Q36805845-8226CD08-1BAB-43CF-8D4D-054DAF895D2FQ36931805-73B132A0-B63F-4551-A7AE-A800734357D7Q36998698-009B8BD9-C280-4019-9C6E-6B9FF0FB0115Q37151528-59D71748-D0B1-42F1-803C-B83ADF77BDAFQ37171415-C9D7E5FB-B325-494C-AB96-E3BD1960A2C0Q37284234-C02A8E47-CA45-48B4-ADF2-A7CC61DD99B9Q37497555-2830EB7A-C9C4-4344-AC50-E76E7E411F33Q37621615-7F5F19AF-78DC-4BD7-BF95-C9D48000640DQ37690121-45F11F52-0F64-45F0-96AC-DE2DF3DA772A
P2860
Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Point-of-care genetic testing ...... mised, proof-of-concept trial.
@ast
Point-of-care genetic testing ...... mised, proof-of-concept trial.
@en
Point-of-care genetic testing ...... mised, proof-of-concept trial.
@nl
type
label
Point-of-care genetic testing ...... mised, proof-of-concept trial.
@ast
Point-of-care genetic testing ...... mised, proof-of-concept trial.
@en
Point-of-care genetic testing ...... mised, proof-of-concept trial.
@nl
prefLabel
Point-of-care genetic testing ...... mised, proof-of-concept trial.
@ast
Point-of-care genetic testing ...... mised, proof-of-concept trial.
@en
Point-of-care genetic testing ...... mised, proof-of-concept trial.
@nl
P2093
P1433
P1476
Point-of-care genetic testing ...... mised, proof-of-concept trial.
@en
P2093
Alexander Dick
Alexandre Stewart
Chris Glover
Derek Y F So
Edward O'Brien
George A Wells
Irena Druce
Jason D Roberts
Jean-Francois Marquis
Marino Labinaz
P304
P356
10.1016/S0140-6736(12)60161-5
P407
P577
2012-03-29T00:00:00Z